Skip to main content

Advertisement

Table 2 KRAS mutations

From: Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease

Exon Codon Hot spot site Amino acid No. of patients %
2 12    24 40.6
   c.34 G>A p.Gly12Ser 1 1.6
   c.35 G>A p.Gly12Asp 15 25.4
   c.35 G>T p.Gly12Val 7 11.8
   c.35 G>C p.Gly12Ala 1 1.6
  13    4 6.7
   c.37_39 dupl p.Gly13 dupl 1 1.6
   c.37 - - -
   c.38 G>A p.Gly13Asp 3 5